X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (62149) 62149
Newsletter (1669) 1669
Newspaper Article (765) 765
Magazine Article (537) 537
Book Chapter (172) 172
Book / eBook (106) 106
Transcript (93) 93
Web Resource (61) 61
Dissertation (33) 33
Conference Proceeding (30) 30
Streaming Video (18) 18
Book Review (13) 13
Government Document (5) 5
Publication (4) 4
Trade Publication Article (4) 4
Journal / eJournal (3) 3
Reference (3) 3
Report (2) 2
Paper (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53542) 53542
antiviral agents - therapeutic use (39868) 39868
female (24163) 24163
male (24038) 24038
antiviral agents (20150) 20150
adult (18500) 18500
middle aged (16239) 16239
treatment outcome (10772) 10772
infectious diseases (10128) 10128
health aspects (9926) 9926
animals (9680) 9680
hepatitis c, chronic - drug therapy (8666) 8666
hiv (8557) 8557
drug therapy, combination (8029) 8029
hiv infections - drug therapy (8000) 8000
infection (7988) 7988
gastroenterology & hepatology (7917) 7917
aged (7428) 7428
interferon-alpha - therapeutic use (7397) 7397
virology (7294) 7294
pharmacology & pharmacy (7221) 7221
antiviral agents - pharmacology (7210) 7210
immunology (6852) 6852
drug therapy (6805) 6805
viruses (6623) 6623
hepatitis c (6425) 6425
ribavirin - therapeutic use (6407) 6407
therapy (6396) 6396
care and treatment (5795) 5795
infections (5767) 5767
antiviral agents - administration & dosage (5691) 5691
analysis (5565) 5565
research (5549) 5549
microbiology (5520) 5520
interferon (5500) 5500
virus diseases (5456) 5456
risk factors (5196) 5196
adolescent (5194) 5194
hepatitis c virus (5150) 5150
antiviral agents - adverse effects (5143) 5143
viral load (5126) 5126
genotype (4625) 4625
hepatitis c - drug therapy (4622) 4622
hepatitis (4533) 4533
hepacivirus - genetics (4452) 4452
ribavirin (4418) 4418
human immunodeficiency virus--hiv (4368) 4368
aids (4352) 4352
hiv infection (4292) 4292
retrospective studies (4209) 4209
hepatitis b, chronic - drug therapy (4163) 4163
young adult (4018) 4018
anti-hiv agents - therapeutic use (3977) 3977
child (3824) 3824
recombinant proteins (3797) 3797
medicine, general & internal (3649) 3649
mice (3633) 3633
time factors (3613) 3613
research article (3612) 3612
highly active antiretroviral therapy (3593) 3593
antiretroviral therapy (3493) 3493
medicine (3492) 3492
acyclovir - therapeutic use (3392) 3392
polyethylene glycols - therapeutic use (3289) 3289
transplantation (3178) 3178
prevention (3089) 3089
hepacivirus - drug effects (3028) 3028
hepatitis b (2948) 2948
virus-infection (2919) 2919
disease (2914) 2914
mortality (2914) 2914
dosage and administration (2834) 2834
virus (2813) 2813
medical research (2798) 2798
multidisciplinary sciences (2746) 2746
hiv infections - complications (2716) 2716
influenza (2694) 2694
liver (2694) 2694
patients (2681) 2681
replication (2671) 2671
hepatitis c, chronic - virology (2642) 2642
virus replication - drug effects (2595) 2595
antiviral therapy (2540) 2540
prospective studies (2534) 2534
influenza, human - drug therapy (2531) 2531
antiviral activity (2530) 2530
recurrence (2497) 2497
child, preschool (2454) 2454
drug resistance (2444) 2444
human-immunodeficiency-virus (2404) 2404
hiv infections - virology (2398) 2398
follow-up studies (2396) 2396
infant (2393) 2393
lamivudine (2391) 2391
ganciclovir - therapeutic use (2355) 2355
drug resistance, viral (2342) 2342
rna (2323) 2323
interferons - therapeutic use (2305) 2305
science (2284) 2284
usage (2283) 2283
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (66) 66
Online Resources - Online (61) 61
Collection Dvlpm't (Acquisitions) - Vendor file (8) 8
UofT at Mississauga - Stacks (8) 8
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
UofT at Scarborough - Stacks (3) 3
Gerstein Science - Periodical Stacks (1) 1
Gerstein Science - Processing (1) 1
Media Commons - Audio Visual (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Government Pubs (1) 1
St. Michael's Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (60805) 60805
French (1064) 1064
Chinese (815) 815
German (737) 737
Spanish (734) 734
Russian (622) 622
Japanese (529) 529
Polish (182) 182
Italian (155) 155
Korean (117) 117
Dutch (108) 108
Hungarian (104) 104
Portuguese (68) 68
Danish (53) 53
Romanian (49) 49
Swedish (33) 33
Czech (31) 31
Finnish (30) 30
Croatian (27) 27
Turkish (25) 25
Hebrew (24) 24
Ukrainian (23) 23
Norwegian (20) 20
Serbian (17) 17
Bulgarian (15) 15
Slovak (7) 7
Arabic (6) 6
Lithuanian (4) 4
Bosnian (2) 2
Icelandic (2) 2
Afrikaans (1) 1
Albanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Antimicrobial agents and chemotherapy, ISSN 0066-4804
Journal
Drug discovery today, ISSN 1359-6446, 2015, Volume 20, Issue 5, pp. 595 - 601
Journal Article
Molecules (Basel, Switzerland), ISSN 1420-3049, 2016, Volume 21, Issue 8, p. 991
Phenylethanoid glycosides (PhGs) are widely distributed in traditional Chinese medicines as well as in other medicinal plants, and they were characterized by a... 
Bioactivity | Pharmacokinetics | Novel structures | Phenylethanoid glycosides | CISTANCHE-SALSA EXTRACT | ALZHEIMERS-DISEASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | novel structures | TANDEM MASS-SPECTROMETRY | CHEMISTRY, MULTIDISCIPLINARY | PERFORMANCE LIQUID-CHROMATOGRAPHY | phenylethanoid glycosides | VITRO ANTIINFLAMMATORY ACTIVITY | IN-VITRO | bioactivity | FORSYTHIA-SUSPENSA | METABOLITE P-TYROSOL | LC-MS/MS METHOD | pharmacokinetics | RAT PLASMA | Neuroprotective Agents - therapeutic use | Antioxidants - chemistry | Antiviral Agents - pharmacokinetics | Immunologic Factors - isolation & purification | Anti-Bacterial Agents - therapeutic use | Immunologic Factors - pharmacokinetics | Neuroprotective Agents - pharmacokinetics | Antiviral Agents - chemistry | Anti-Bacterial Agents - chemistry | Glycosides - isolation & purification | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - pharmacokinetics | Anti-Inflammatory Agents - isolation & purification | Drugs, Chinese Herbal - therapeutic use | Glycosides - chemistry | Immunologic Factors - chemistry | Plants, Medicinal - chemistry | Neuroprotective Agents - chemistry | Antiviral Agents - therapeutic use | Phenylethyl Alcohol - pharmacokinetics | Anti-Bacterial Agents - isolation & purification | Phenylethyl Alcohol - isolation & purification | Drugs, Chinese Herbal - pharmacokinetics | Antioxidants - therapeutic use | Anti-Inflammatory Agents - chemistry | Neuroprotective Agents - isolation & purification | Antioxidants - isolation & purification | Drugs, Chinese Herbal - chemistry | Anti-Bacterial Agents - pharmacokinetics | Glycosides - pharmacokinetics | Antioxidants - pharmacokinetics | Antiviral Agents - isolation & purification | Phenylethyl Alcohol - therapeutic use | Glycosides - therapeutic use | Immunologic Factors - therapeutic use | Phenylethyl Alcohol - chemistry
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 308 - 317
...) as an important negative prognostic biomarker Given that CXCL10 mediates chemoattraction of activated lymphocytes, it is counter-intuitive that this chemokine correlates with therapeutic... 
MEDICINE, RESEARCH & EXPERIMENTAL | LIVER INFLAMMATION | GAMMA-INDUCIBLE PROTEIN-10 | VIRUS-INFECTION | DIPEPTIDYL-PEPTIDASE-IV | ANTIVIRAL THERAPY | INSULIN-RESISTANCE | IMMUNE-RESPONSES | CHRONIC HEPATITIS-C | LEVELS CORRELATE | PEGINTERFERON PLUS RIBAVIRIN | Chemokine CXCL10 - blood | Prognosis | Antiviral Agents - therapeutic use | Receptors, CXCR3 - blood | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Chemokine CXCL10 - antagonists & inhibitors | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Hepatitis C, Chronic - therapy | Recombinant Proteins | Hepatitis C, Chronic - blood | Polyethylene Glycols - therapeutic use | T-Lymphocytes - virology | Treatment Failure | Hepatitis C, Chronic - immunology | Peptide Fragments - blood | Protein Array Analysis | T-Lymphocytes - immunology | Proteases | Physiological aspects | Research | Diagnosis | Hepatitis C | Drug therapy | Chemokines | Hepatitis C, Chronic/therapy | T-Lymphocytes/immunology | Polyethylene Glycols/therapeutic use | Dipeptidyl Peptidase 4/blood | Receptors, CXCR3/blood | Chemokine CXCL10/blood | T-Lymphocytes/virology | Hepatitis C, Chronic/blood | Interferon-alpha/therapeutic use | Chemokine CXCL10/antagonists & inhibitors | Life Sciences | Immunology | Antiviral Agents/therapeutic use | Hepatitis C, Chronic/immunology | Peptide Fragments/blood | Ribavirin/therapeutic use | Hepatitis C, Chronic/virology
Journal Article
Trends in biotechnology (Regular ed.), ISSN 0167-7799, 2004, Volume 22, Issue 3, pp. 142 - 146
...-adhesive agents to pathogens, making them useful for treating many diseases and as therapeutic and probiotic agents... 
IN-VITRO | ITURIN-A | ANTIBIOTICS | ACTIVATION | BACILLUS-SUBTILIS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ENHANCEMENT | MANNOSYLERYTHRITOL LIPIDS | BIOSURFACTANTS | GENE TRANSFECTION | PLASMINOGEN | Fibrinolysis - drug effects | Surface-Active Agents - therapeutic use | Antibiotics, Antineoplastic - pharmacology | Gram-Positive Bacteria - drug effects | Anti-Infective Agents - pharmacology | Humans | Peptides, Cyclic - pharmacology | Peptides, Cyclic - chemistry | Antifungal Agents - therapeutic use | Anti-Bacterial Agents - therapeutic use | Anti-Infective Agents - chemistry | Fibrinolytic Agents - therapeutic use | Glycolipids - chemistry | Bacterial Adhesion - drug effects | Antifungal Agents - pharmacology | Antiviral Agents - pharmacology | Peptides - chemistry | Antiviral Agents - therapeutic use | Glycolipids - pharmacology | Anti-Infective Agents - therapeutic use | Peptides - pharmacology | Surface-Active Agents - pharmacology | Fibrinolytic Agents - pharmacology | Antibiotics, Antineoplastic - therapeutic use | Cell Differentiation - drug effects | Lipoproteins - pharmacology | Peptides, Cyclic - therapeutic use | Anti-Bacterial Agents - pharmacology | Surface-Active Agents - chemistry | Lipopeptides | Peptides - therapeutic use | Salmonella | Signal transduction | Probiotics | E coli | Herpes viruses | Antimicrobial agents | Lipids | Genetic engineering | Drug resistance | Surfactants | Bacteriology
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | SEXUAL TRANSMISSION | HEPATITIS-C VIRUS | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | PEGYLATED INTERFERON-ALPHA-2B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133236
Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy.... 
VIRUS-INFECTION | CHEMOKINES | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PROTEIN-10 | GENOTYPE 1 INFECTION | PREDICTIVE-VALUE | RIBAVIRIN | INDUCTION | ASSOCIATION | SPONTANEOUS CLEARANCE | Recurrence | Interferons | Humans | Fluorenes - therapeutic use | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Male | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Virus Replication - drug effects | Chemokine CXCL10 - blood | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Convalescence | Chemokine CXCL10 - genetics | Protein Processing, Post-Translational | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Infection | Care and treatment | Analysis | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Therapy | Laboratories | Chronic infection | Critical care | Amino acids | Infections | Ribavirin | Clinical outcomes | Proteins | Genotype & phenotype | Hepatitis | Immunology | Hepatology | Post-translation | Pretreatment | Drug dosages | Genotypes | Statistical analysis | Liver diseases | Dendritic cells | Serum levels | Studies | Infectious diseases | CXCL10 protein | Biomarkers | Chemokines | Virus Replication/drug effects | Viral Load/drug effects | Dipeptidyl Peptidase 4/blood | Dipeptidyl Peptidase 4/genetics | Chemokine CXCL10/blood | Hepatitis C, Chronic/blood | Life Sciences | Hepatitis C, Chronic/drug therapy | Hepatitis C, Chronic/virology | Hepatitis C, Chronic/genetics | Chemokine CXCL10/genetics | Benzimidazoles/therapeutic use | Hepacivirus/physiology | Fluorenes/therapeutic use | Antiviral Agents/therapeutic use | Sofosbuvir/therapeutic use | Hepacivirus/drug effects | Ribavirin/therapeutic use
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
.... This review article is structured to discuss antiviral therapeutics on the basis of these 3 major antiviral categories, with the caveat that some drugs discussed... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | CONGO HEMORRHAGIC-FEVER | ACUTE INTERSTITIAL NEPHRITIS | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Valacyclovir | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Valganciclovir | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Telbivudine | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article